Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
ALX Oncology Holdings (ALXO)
NASDAQ:ALXO
ALX Oncology Holdings (ALXO) Stock Price & Analysis
294 Followers
ALXO Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.94 - $17.83
Previous Close$5.99
Volume473.30K
Average Volume (3M)803.33K
Market Cap
$312.08M
Enterprise Value$164.35M
Total Cash (Recent Filing)$157.44M
Total Debt (Recent Filing)$9.70M
Price to Earnings (P/E)―
Beta1.74
Next Earnings
Aug 07, 2024EPS Estimate
-$0.74Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.71
Shares Outstanding52,100,107
10 Day Avg. Volume696,156
30 Day Avg. Volume803,332
Standard Deviation0.30
R-Squared0.04
Alpha0.00119
Financial Highlights & Ratios
Price to Book (P/B)1.80
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.99
Forecast
1Y Price Target
$20.80Price Target Upside263.64% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
ALX Oncology Holdings News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe combination of evorpacept and Padcev showed a 63% overall response rate in patients with urothelial cancer who received prior chemotherapy and a PD-(L)1 inhibitor.
Drug EfficacyEvorpacept combined with SOC shows potential in difficult r/r NHL population, with a CR rate of 83%, which compared favorably to the benchmark rate of 34%.
EarningsAnalysts maintain a Buy rating of ALXO with a 12-month price target of $20, based on a risk-adjusted net present value analysis of projected future revenues from evorpacept.
Bears Say
Data InterpretationThe spider plot in the poster was difficult to interpret in terms of which patients remain on study and which patients are the unconfirmed vs. confirmed responders.
Efficacy IssuesALX previously announced they were discontinuing the program combining evorpacept with azacitidine in MDS patients due to lack of efficacy.
Safety Concerns25% of patients experienced evo-related Grade 3-4 adverse events, including serious issues like neutrophil count decrease, thrombocytopenia, and anemia.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
ALXO FAQ
What was ALX Oncology Holdings’s price range in the past 12 months?
ALX Oncology Holdings lowest stock price was $3.94 and its highest was $17.82 in the past 12 months.
What is ALX Oncology Holdings’s market cap?
Currently, no data Available
When is ALX Oncology Holdings’s upcoming earnings report date?
ALX Oncology Holdings’s upcoming earnings report date is Aug 07, 2024 which is in 35 days.
How were ALX Oncology Holdings’s earnings last quarter?
ALX Oncology Holdings released its earnings results on May 09, 2024. The company reported -$0.71 earnings per share for the quarter, beating the consensus estimate of -$0.817 by $0.107.
Is ALX Oncology Holdings overvalued?
According to Wall Street analysts ALX Oncology Holdings’s price is currently Undervalued.
Does ALX Oncology Holdings pay dividends?
ALX Oncology Holdings does not currently pay dividends.
What is ALX Oncology Holdings’s EPS estimate?
ALX Oncology Holdings’s EPS estimate is -$0.74.
How many shares outstanding does ALX Oncology Holdings have?
ALX Oncology Holdings has 52,100,105 shares outstanding.
What happened to ALX Oncology Holdings’s price movement after its last earnings report?
ALX Oncology Holdings reported an EPS of -$0.71 in its last earnings report, beating expectations of -$0.817. Following the earnings report the stock price went down -4.366%.
Which hedge fund is a major shareholder of ALX Oncology Holdings?
Among the largest hedge funds holding ALX Oncology Holdings’s share is EntryPoint Capital, LLC. It holds ALX Oncology Holdings’s shares valued at 32K.
---
ALX Oncology Holdings Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$20.80 (263.64% Upside)
$20.80 (263.64% Upside)
Blogger Sentiment
Bullish
ALXO Sentiment 78%
Sector Average 72%
Sector Average 72%
Insider Transactions
Bought Shares
Worth $102.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.4%
Last 30 Days ▲ 51.4%
Last 30 Days ▲ 51.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-20.23%
12-Months-Change
Fundamentals
Return on Equity
-82.16%
Trailing 12-Months
Asset Growth
-23.55%
Trailing 12-Months
Company Description
ALX Oncology Holdings
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company. The firm is focused on developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system.
---
ALXO Stock 12 Month Forecast
Average Price Target
$20.80
▲(263.64% Upside)
Technical Analysis
Best Analysts Covering ALXO
1 Year
1 Year Success Rate
5/18 ratings generated profit
1 Year Average Return
-16.18%
reiterated a buy rating 23 days ago
Copying Swayampakula Ramakanth's trades and holding each position for 1 Year would result in 27.78% of your transactions generating a profit, with an average return of -16.18% per trade.
---